×

Metformin Reverses Myotonic Dystrophy Symptoms in Cells

Share







Metformin structureMetformin structure

A new study published in Aging shows that metformin, a drug that has been studied for its effects on longevity, restores mitochondrial function and repairs metabolic defects in cells from people with myotonic dystrophy, a condition that shares many of the same characteristics as aging.

A genetic disease that causes age-related symptoms

Myotonic dystrophy is a genetic disease that causes muscular weakness and atrophy along with multiple other disorders. As the researchers explain, it has two main types: DM1 and DM2. DM1 is both more severe and more common, and the researchers note that its effects share many similarities with the hallmarks of aging, including cellular senescence, genomic instability, telomere attrition, and deregulated nutrient sensing.

DM1 also harms the ability of mitochondria to perform their most fundamental task, which is the conversion of food into ATP; it causes one major pathway, oxidative phosphorlyzation (OXPHOS), to lose half of its ability to do this. DM1 cells also respond poorly to metabolic stresses, being largely unable to increase production when needed.

Restoring respiration

As a potential treatment for this disease, the researchers of this study turned to metformin, a drug that is known to have a beneficial influence on mitochondria [1].

The results of the study were clear. As the graphs show, the use of metformin resulted in increases of cellular respiration and ATP production close to the level of the control group, and it substantially reduced production of hydrogen peroxide, a reactive oxygen species (ROS) that leads to oxidative damage.

Results of metformin in a DM1 cell study

The study also showed that metformin increases cell division and viability in DM1 cells, decreasing markers of senescence such as p16Ink4a and p21CIP.

Abstract

ADVERTISEMENT

Novos-labs Ads 3

Myotonic dystrophy type 1 (DM1; MIM #160900) is an autosomal dominant disorder, clinically characterized by progressive muscular weakness and multisystem degeneration. The broad phenotypes observed in patients with DM1 resemble the appearance of a multisystem accelerated aging process. However, the molecular mechanisms underlying these phenotypes remain largely unknown. In this study, we characterized the impact of metabolism and mitochondria on fibroblasts and peripheral blood mononuclear cells (PBMCs) derived from patients with DM1 and healthy individuals. Our results revealed a decrease in oxidative phosphorylation system (OXPHOS) activity, oxygen consumption rate (OCR), ATP production, energy metabolism, and mitochondrial dynamics in DM1 fibroblasts, as well as increased accumulation of reactive oxygen species (ROS). PBMCs of DM1 patients also displayed reduced mitochondrial dynamics and energy metabolism. Moreover, treatment with metformin reversed the metabolic and mitochondrial defects as well as additional accelerated aging phenotypes, such as impaired proliferation, in DM1-derived fibroblasts. Our results identify impaired cell metabolism and mitochondrial dysfunction as important drivers of DM1 pathophysiology and, therefore, reveal the efficacy of metformin treatment in a pre-clinical setting.

Conclusion

This is a cell study, not a clinical trial. While the cells used are from human beings and not mice, the results of cell studies cannot always be replicated in clinical trials. Additionally, as myotonic dystrophy is a genetic disease, the only potential true cure is a genetic one; while drugs such as metformin may be instrumental in treating the symptoms, they cannot treat the cause.

That said, however, it may be possible that metformin will offer new hope for sufferers of myotonic dystrophy or other disorders that negatively impact metabolism, and this study also helps put together disparate hallmarks of aging, such as mitochondrial dysfunction and cellular senescence.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future.

Literature

Wang Y, An H, Liu T, Qin C, Sesaki H, Guo S, Radovick S, Hussain M, Maheshwari A, Wondisford FE, O’Rourke B, He L. Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK. Cell Rep. 2019; 29:1511–1523.e5.

About the author
Josh Conway
Josh Conway
Josh is a professional editor and is responsible for editing our articles before they become available to the public as well as moderating our Discord server. He is also a programmer, long-time supporter of anti-aging medicine, and avid player of the strange game called “real life.” Living in the center of the northern prairie, Josh enjoys long bike rides before the blizzards hit.